Search Login Register
lapatinib
(GW572016)
Summary
Description:
an EGFR-ErbB-2 inhibitor
Also Known As:
GW572016; GW 282974X; GW 572016; GW-282974X; GW-572016 Show All >>
Networked: 1024
relevant articles (162 outcomes,
354 trials/studies)
for this Drug
Key Diseases for which lapatinib is
Relevant
-
Breast Neoplasms (Breast Cancer)
:
103 outcomes 212 studies in 624 results
-
Neoplasms (Cancer)
:
34 outcomes 88 studies in 369 results
-
Neoplasm Metastasis (Metastasis)
:
20 outcomes 27 studies in 99 results
-
Carcinoma (Carcinomatosis)
:
4 outcomes 6 studies in 32 results
-
Stomach Neoplasms (Stomach Cancer)
:
3 outcomes 12 studies in 24 results
Show All >>
Drugs Related to lapatinib
-
trastuzumab (Herceptin)
-
capecitabine (Xeloda)
-
Epidermal Growth Factor Receptor (EGF Receptor)
-
Protein-Tyrosine Kinases (Tyrosine Kinase)
-
Phosphotransferases (Kinase)
-
Hormones
-
letrozole (Femara)
-
Aromatase (CYP19)
-
Paclitaxel (Taxol)
-
taxane
Show All >>
Therapies Related to lapatinib
-
Drug Therapy (Chemotherapy)
-
Heterologous Transplantation (Xenotransplantation)
-
Aftercare (After-Treatment)
-
Neoadjuvant Therapy
-
Radiotherapy
Show All >>
CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.